CB
Carlo Boutton
Biotalys
Chief Scientific Officer
Description
Carlo Boutton obtained his PhD in 1999 at the University of Leuven (Belgium) on a subject that investigated the physico-chemical behavior of proteins under high-electromagnetic (laser) fields.
After his PhD he joined Algonomics, a small start-up that focused on rational design of therapeutics in the broad field of immunotherapy.
In 2003 he moved to Tibotec (a subsidiary of Johnson & Johnson) where he supported multiple HIV and HCV discovery programs via a structure-based design and chemo-informatics approach.
He started working with single domain antibodies, so called Nanobodies in 2007, when joining Ablynx where he held multiple positions. Throughout his Ablynx tenure he mainly focused on improvements of the NANOBODY® platform and on new therapeutic applications for single domain antibodies, such as multispecifics, immunotherapeutics and antibody-drug-conjugates. He was also involved in multiple external collaborations as member of Joint Steering Committees. After the acquisition of Ablynx by Sanofi he continued focusing on innovation.
In his last position as Global Head Innovation for Large Molecules Research he was responsible for all innovation efforts of all biological modalities, including Nanobodies, antibodies and cytokines. In May 2022 he joined Biotalys as Chief Scientific Officer to focus on the technology platform and the research pipeline. He is responsible for all research and early development activities and is leading a multidisciplinary team of ~50 scientists. Carlo is co-inventor on more than 20 patent applications and brings more 20 years of R&D expertise to Biotalys.
Loading